Literature DB >> 3240729

Hypertensive patients with Raynaud's phenomenon or intermittent claudication and their treatment with ketanserin.

J C van Oene1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3240729     DOI： 10.2165/00003495-198800361-00030

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  6 in total

1.  Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy.

Authors:  J J Kunnen; H P Dahler; J G Doorenspleet; J C van Oene
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications.

Authors:  O Thulesius; J Lundvall; A Kroese; E Stranden; T Hallböök; L Brunes; J E Gjöres; H Akesson; E Einarsson; P Ohlin
Journal:  J Cardiovasc Pharmacol       Date:  1987-06       Impact factor: 3.105

3.  Serum cholesterol during ketanserin and propranolol administration in hypertensive patients.

Authors:  P Lijnen; R Fagard; J Staessen; V Blaton; P Hollez; G Rorive; A Amery
Journal:  J Cardiovasc Pharmacol       Date:  1987-12       Impact factor: 3.105

4.  Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.

Authors:  O K Roald; E Seem
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-08

5.  Comparison of ketanserin and metoprolol in the treatment of essential hypertension.

Authors:  S G Sheps; A Schirger; P K Zachariah; L D Fisher; R E Spiekerman; F J Araas; J B Collins; D C Agerter
Journal:  Arch Intern Med       Date:  1987-02

6.  5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency.

Authors:  G J Wenting; A J Woittiez; A J Man in't Veld; M A Schalekamp
Journal:  Hypertension       Date:  1984 Jan-Feb       Impact factor: 10.190
  6 in total
  2 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Oral dosing with ketanserin to control high blood pressure in the elderly.

Authors:  J C van Oene
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.